2023-05-30 01:13:59 ET
- Burning Rock Biotech press release ( NASDAQ: BNR ): Q1 GAAP EPS of -$0.26.
- Revenue of $20.8M (-2.8% Y/Y).
- Non-GAAP gross margin was 75.7% for the three months ended March 31, 2023, compared to 68.4% for the same period in 2022.
-
Cash, cash equivalents, restricted cash and short-term investments were $116.9M as of March 31, 2023.
-
2023 Financial Guidance: We reiterate our 2023 full-year revenue guidance of approximately 20% growth over 2022 vs. estimated growth of 20.1% Y/Y.
For further details see:
Burning Rock Biotech GAAP EPS of -$0.26, revenue of $20.8M; reaffirms FY23 guidance